Skip to content
OpenCapital
Get started

Citius Oncology, Inc. CTOR Net Sales Percentage

Net Sales Percentage at other companies

Evommune logo
Evommune EVMN
96%+3.0pp
Lands' End, Inc. logo
Lands' End, Inc.LE
23.1%+0.3pp
Evommune logo
Evommune EVMN
96%+3.0pp
CTO
Citius Oncology, Inc.CTOR
50%0.0pp
RBC Bearings logo
RBC BearingsRBC
13%-5.0pp
Microbot Medical logo
Microbot MedicalMBOT
3%0.0pp

Other financials

Income statement

See full
Revenue$1.7M—
Gross profit$1.3M—
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept ctor:NetSalesPercentage.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s net sales percentage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s net sales percentage?
Citius Oncology, Inc. (CTOR) reported net sales percentage of 50% in Q1 2026.
How has Citius Oncology, Inc.'s net sales percentage changed year-over-year?
Citius Oncology, Inc.'s net sales percentage decreased by 0.0% year-over-year, from 50% to 50%.
What does net sales percentage mean?
The ratio of a specific revenue stream or product line's sales relative to the total net sales of the company. This metric highlights the concentration risk or the relative importance of a particular drug or therapeutic area to the overall business performance. It provides insight into the diversification of the company's revenue portfolio.